ORGANON BIOTHERAPEUTICS SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGN

Core Viewpoint - A securities class action lawsuit has been filed against Organon & Co. for failing to disclose material information during the class period, which has led to significant financial repercussions for investors [3][4]. Group 1: Lawsuit Details - Investors have until July 22, 2025, to file lead plaintiff applications if they purchased Organon securities between October 31, 2024, and April 30, 2025 [1]. - The lawsuit is pending in the United States District Court for the District of New Jersey, under the case name Hauser V. Organon & Co., et al., No. 25-cv-05322 [5]. - The company and certain executives are accused of violating federal securities laws by not disclosing critical information during the class period [3]. Group 2: Financial Impact - On March 10, 2025, Organon announced a significant reduction in its dividend payout from $0.28 to $0.02, which contradicted previous assurances to investors regarding the importance of maintaining the dividend [4]. - Following the announcement, Organon's share price dropped over 27%, from $12.93 on April 30, 2025, to $9.45 on May 1, 2025 [4]. Group 3: Investor Support - ClaimsFiler provides resources for investors to recover funds from securities class action settlements, including free registration for information on various cases [6]. - Investors can upload their portfolio data to receive notifications about relevant securities cases and can seek free case evaluations from the law firm Kahn Swick & Foti, LLC [6].